US 12281173
Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 12281173 (Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K9/0019